Viewing Study NCT05807932

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:24 PM
Ignite Modification Date: 2026-05-10 @ 6:23 PM
Study NCT ID: NCT05807932
Status: RECRUITING
Last Update Posted: 2024-05-01
First Post: 2023-03-03
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Sponsor: Heinrich-Heine University, Duesseldorf
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myelodysplastic Syndromes View
None Secondary Acute Myeloid Leukemia View
None Chronic Myelomonocytic Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None MDS View
None sAML View
None CMML View
None allogeneic blood stem cell transplantation View
None Venetoclax View